Mucosal healing in inflammatory bowel disease - A true paradigm of success?

Research output: Contribution to journalReview article

85 Citations (Scopus)

Abstract

Mucosal healing is gaining more acceptance as a measure of disease activity in Crohn's disease and ulcerative colitis, and it is also gaining acceptance as an endpoint in clinical trials. Recent publications have correlated achievement of mucosal healing with good outcomes. Currently, there is no validated definition of what constitutes mucosal healing in inflammatory bowel disease. In clinical trials of ulcerative colitis, mucosal healing has been achieved with 5-aminosalicylates, corticosteroids, azathioprine, and infliximab. For Crohn's disease, mucosal healing has been achieved with corticosteroids, infliximab, and adalimumab, and mucosal healing has been maintained with infliximab. Achievement of long-term mucosal healing has been associated with a decreased risk of colectomy and colorectal cancer in ulcerative colitis patients, a decreased need for corticosteroid treatment in Crohn's disease patients, and a trend toward a decreased need for hospitalization in Crohn's disease patients. Unfortunately, assessment of mucosal healing requires regular use of endoscopy, which is associated with increased costs, patient discomfort, and side effects. Biomarkers such as fecal calprotectin, fecal lactoferrin, serum C-reactive protein, and fecal S100A12 have been shown to correlate with disease activity in ulcerative colitis and Crohn's disease; in the future, these biomarkers might be used as surrogate markers for mucosal healing. Newer clinical trials are incorporating mucosal healing as an endpoint for evaluation of efficacy. However, before mucosal healing will be sufficient to guide therapy, clinicians need a standard definition of mucosal healing and a consistently used, prospectively validated scale with good interobserver agreement.

Original languageEnglish (US)
Pages (from-to)29-38
Number of pages10
JournalGastroenterology and Hepatology
Volume8
Issue number1
StatePublished - Jan 2012

Fingerprint

Inflammatory Bowel Diseases
Crohn Disease
Ulcerative Colitis
Adrenal Cortex Hormones
Biomarkers
Clinical Trials
Leukocyte L1 Antigen Complex
Mesalamine
Lactoferrin
Colectomy
Azathioprine
C-Reactive Protein
Endoscopy
Blood Proteins
Colorectal Neoplasms
Hospitalization
Costs and Cost Analysis
Therapeutics
Infliximab

Keywords

  • Anti-tumor necrosis factor agents
  • Colonoscopy
  • Corticosteroids
  • Crohn's disease
  • Mucosal healing
  • Ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Mucosal healing in inflammatory bowel disease - A true paradigm of success? / Dave, Maneesh; Loftus, Jr, Edward Vincent.

In: Gastroenterology and Hepatology, Vol. 8, No. 1, 01.2012, p. 29-38.

Research output: Contribution to journalReview article

@article{abc25733a0144d6fb91b4026fa42b8f2,
title = "Mucosal healing in inflammatory bowel disease - A true paradigm of success?",
abstract = "Mucosal healing is gaining more acceptance as a measure of disease activity in Crohn's disease and ulcerative colitis, and it is also gaining acceptance as an endpoint in clinical trials. Recent publications have correlated achievement of mucosal healing with good outcomes. Currently, there is no validated definition of what constitutes mucosal healing in inflammatory bowel disease. In clinical trials of ulcerative colitis, mucosal healing has been achieved with 5-aminosalicylates, corticosteroids, azathioprine, and infliximab. For Crohn's disease, mucosal healing has been achieved with corticosteroids, infliximab, and adalimumab, and mucosal healing has been maintained with infliximab. Achievement of long-term mucosal healing has been associated with a decreased risk of colectomy and colorectal cancer in ulcerative colitis patients, a decreased need for corticosteroid treatment in Crohn's disease patients, and a trend toward a decreased need for hospitalization in Crohn's disease patients. Unfortunately, assessment of mucosal healing requires regular use of endoscopy, which is associated with increased costs, patient discomfort, and side effects. Biomarkers such as fecal calprotectin, fecal lactoferrin, serum C-reactive protein, and fecal S100A12 have been shown to correlate with disease activity in ulcerative colitis and Crohn's disease; in the future, these biomarkers might be used as surrogate markers for mucosal healing. Newer clinical trials are incorporating mucosal healing as an endpoint for evaluation of efficacy. However, before mucosal healing will be sufficient to guide therapy, clinicians need a standard definition of mucosal healing and a consistently used, prospectively validated scale with good interobserver agreement.",
keywords = "Anti-tumor necrosis factor agents, Colonoscopy, Corticosteroids, Crohn's disease, Mucosal healing, Ulcerative colitis",
author = "Maneesh Dave and {Loftus, Jr}, {Edward Vincent}",
year = "2012",
month = "1",
language = "English (US)",
volume = "8",
pages = "29--38",
journal = "Gastroenterology and Hepatology",
issn = "1554-7914",
publisher = "Gastro-Hep Communications, Inc.",
number = "1",

}

TY - JOUR

T1 - Mucosal healing in inflammatory bowel disease - A true paradigm of success?

AU - Dave, Maneesh

AU - Loftus, Jr, Edward Vincent

PY - 2012/1

Y1 - 2012/1

N2 - Mucosal healing is gaining more acceptance as a measure of disease activity in Crohn's disease and ulcerative colitis, and it is also gaining acceptance as an endpoint in clinical trials. Recent publications have correlated achievement of mucosal healing with good outcomes. Currently, there is no validated definition of what constitutes mucosal healing in inflammatory bowel disease. In clinical trials of ulcerative colitis, mucosal healing has been achieved with 5-aminosalicylates, corticosteroids, azathioprine, and infliximab. For Crohn's disease, mucosal healing has been achieved with corticosteroids, infliximab, and adalimumab, and mucosal healing has been maintained with infliximab. Achievement of long-term mucosal healing has been associated with a decreased risk of colectomy and colorectal cancer in ulcerative colitis patients, a decreased need for corticosteroid treatment in Crohn's disease patients, and a trend toward a decreased need for hospitalization in Crohn's disease patients. Unfortunately, assessment of mucosal healing requires regular use of endoscopy, which is associated with increased costs, patient discomfort, and side effects. Biomarkers such as fecal calprotectin, fecal lactoferrin, serum C-reactive protein, and fecal S100A12 have been shown to correlate with disease activity in ulcerative colitis and Crohn's disease; in the future, these biomarkers might be used as surrogate markers for mucosal healing. Newer clinical trials are incorporating mucosal healing as an endpoint for evaluation of efficacy. However, before mucosal healing will be sufficient to guide therapy, clinicians need a standard definition of mucosal healing and a consistently used, prospectively validated scale with good interobserver agreement.

AB - Mucosal healing is gaining more acceptance as a measure of disease activity in Crohn's disease and ulcerative colitis, and it is also gaining acceptance as an endpoint in clinical trials. Recent publications have correlated achievement of mucosal healing with good outcomes. Currently, there is no validated definition of what constitutes mucosal healing in inflammatory bowel disease. In clinical trials of ulcerative colitis, mucosal healing has been achieved with 5-aminosalicylates, corticosteroids, azathioprine, and infliximab. For Crohn's disease, mucosal healing has been achieved with corticosteroids, infliximab, and adalimumab, and mucosal healing has been maintained with infliximab. Achievement of long-term mucosal healing has been associated with a decreased risk of colectomy and colorectal cancer in ulcerative colitis patients, a decreased need for corticosteroid treatment in Crohn's disease patients, and a trend toward a decreased need for hospitalization in Crohn's disease patients. Unfortunately, assessment of mucosal healing requires regular use of endoscopy, which is associated with increased costs, patient discomfort, and side effects. Biomarkers such as fecal calprotectin, fecal lactoferrin, serum C-reactive protein, and fecal S100A12 have been shown to correlate with disease activity in ulcerative colitis and Crohn's disease; in the future, these biomarkers might be used as surrogate markers for mucosal healing. Newer clinical trials are incorporating mucosal healing as an endpoint for evaluation of efficacy. However, before mucosal healing will be sufficient to guide therapy, clinicians need a standard definition of mucosal healing and a consistently used, prospectively validated scale with good interobserver agreement.

KW - Anti-tumor necrosis factor agents

KW - Colonoscopy

KW - Corticosteroids

KW - Crohn's disease

KW - Mucosal healing

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=84856913526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856913526&partnerID=8YFLogxK

M3 - Review article

C2 - 22347830

AN - SCOPUS:84856913526

VL - 8

SP - 29

EP - 38

JO - Gastroenterology and Hepatology

JF - Gastroenterology and Hepatology

SN - 1554-7914

IS - 1

ER -